Jump to content
RemedySpot.com

Merck's Big Day: A Share Buyback and FDA Panel Approval

Rate this topic


Guest guest

Recommended Posts

Guest guest

Merck's Big Day: A Share Buyback and FDA Panel Approval

From the PharmaLive.com News Archive - Apr. 28, 2011

Merck & Co., said yesterday morning that it would spend $5 billion to buyback

shares. Then, in the afternoon, it won a recommendation from an FDA advisory

panel for its highly-anticipated hepatitis C drug. The FDA advisory panel voted

18-0 to recommend boceprevir, which will have the brand name Victrelis, as a

more effective treatment than those available at the moment.

Link to comment
Share on other sites

Guest guest

Merck's Big Day: A Share Buyback and FDA Panel Approval

From the PharmaLive.com News Archive - Apr. 28, 2011

Merck & Co., said yesterday morning that it would spend $5 billion to buyback

shares. Then, in the afternoon, it won a recommendation from an FDA advisory

panel for its highly-anticipated hepatitis C drug. The FDA advisory panel voted

18-0 to recommend boceprevir, which will have the brand name Victrelis, as a

more effective treatment than those available at the moment.

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...